158 related articles for article (PubMed ID: 34329704)
21. Performance of candidate urinary biomarkers for pancreatic cancer - Correlation with pancreatic cyst malignant progression?
Yip-Schneider MT; Soufi M; Carr RA; Flick KF; Wu H; Colgate CL; Schmidt CM
Am J Surg; 2020 Mar; 219(3):492-495. PubMed ID: 31554598
[TBL] [Abstract][Full Text] [Related]
22. UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept.
Martinez-Useros J; Georgiev-Hristov T; Fernández-Aceñero MJ; Borrero-Palacios A; Indacochea A; Guerrero S; Li W; Cebrián A; Gómez Del Pulgar T; Puime-Otin A; Del Puerto-Nevado L; Rodríguez-Remírez M; Pérez N; Celdrán A; Gebauer F; Garcia-Foncillas J
PLoS One; 2017; 12(8):e0182044. PubMed ID: 28763470
[TBL] [Abstract][Full Text] [Related]
23. Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients.
Blyuss O; Zaikin A; Cherepanova V; Munblit D; Kiseleva EM; Prytomanova OM; Duffy SW; Crnogorac-Jurcevic T
Br J Cancer; 2020 Mar; 122(5):692-696. PubMed ID: 31857725
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical expression of NEDD9, E-cadherin and γ-catenin and their prognostic significance in pancreatic ductal adenocarcinoma (PDAC).
Radulović P; Krušlin B
Bosn J Basic Med Sci; 2018 Aug; 18(3):246-251. PubMed ID: 29924959
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive analysis of the transcriptional expressions and prognostic value of S100A family in pancreatic ductal adenocarcinoma.
Li HB; Wang JL; Jin XD; Zhao L; Ye HL; Kuang YB; Ma Y; Jiang XY; Yu ZY
BMC Cancer; 2021 Sep; 21(1):1039. PubMed ID: 34530774
[TBL] [Abstract][Full Text] [Related]
26. Serum biomarker panels for the detection of pancreatic cancer.
Brand RE; Nolen BM; Zeh HJ; Allen PJ; Eloubeidi MA; Goldberg M; Elton E; Arnoletti JP; Christein JD; Vickers SM; Langmead CJ; Landsittel DP; Whitcomb DC; Grizzle WE; Lokshin AE
Clin Cancer Res; 2011 Feb; 17(4):805-16. PubMed ID: 21325298
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB
J Transl Med; 2014 Apr; 12():102. PubMed ID: 24745825
[TBL] [Abstract][Full Text] [Related]
28. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
29. Noninvasive prognostic biomarker potential of quantifying the propeptides of Type XI collagen alpha-1 chain (PRO-C11) in patients with pancreatic ductal adenocarcinoma.
Nissen NI; Kehlet S; Johansen AZ; Chen IM; Karsdal M; Johansen JS; Diab HMH; Jørgensen LN; Sun S; Manon-Jensen T; He Y; Langholm L; Willumsen N
Int J Cancer; 2021 Jul; 149(1):228-238. PubMed ID: 33687786
[TBL] [Abstract][Full Text] [Related]
30. A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer.
Fahrmann JF; Bantis LE; Capello M; Scelo G; Dennison JB; Patel N; Murage E; Vykoukal J; Kundnani DL; Foretova L; Fabianova E; Holcatova I; Janout V; Feng Z; Yip-Schneider M; Zhang J; Brand R; Taguchi A; Maitra A; Brennan P; Max Schmidt C; Hanash S
J Natl Cancer Inst; 2019 Apr; 111(4):372-379. PubMed ID: 30137376
[TBL] [Abstract][Full Text] [Related]
31. Expression of kallikrein-related peptidase 7 predicts poor prognosis in patients with unresectable pancreatic ductal adenocarcinoma.
Iakovlev V; Siegel ER; Tsao MS; Haun RS
Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1135-42. PubMed ID: 22573795
[TBL] [Abstract][Full Text] [Related]
32. A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile.
Cote GA; Gore AJ; McElyea SD; Heathers LE; Xu H; Sherman S; Korc M
Am J Gastroenterol; 2014 Dec; 109(12):1942-52. PubMed ID: 25350767
[TBL] [Abstract][Full Text] [Related]
33. Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma.
Radon TP; Massat NJ; Jones R; Alrawashdeh W; Dumartin L; Ennis D; Duffy SW; Kocher HM; Pereira SP; Guarner posthumous L; Murta-Nascimento C; Real FX; Malats N; Neoptolemos J; Costello E; Greenhalf W; Lemoine NR; Crnogorac-Jurcevic T
Clin Cancer Res; 2015 Aug; 21(15):3512-21. PubMed ID: 26240291
[TBL] [Abstract][Full Text] [Related]
34. Biomarkers in pancreatic ductal adenocarcinoma.
Gallego J; López C; Pazo-Cid R; López-Ríos F; Carrato A
Clin Transl Oncol; 2017 Dec; 19(12):1430-1437. PubMed ID: 28616721
[TBL] [Abstract][Full Text] [Related]
35. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
[TBL] [Abstract][Full Text] [Related]
36. Identifying molecular subtypes related to clinicopathologic factors in pancreatic cancer.
Kim S; Kang M; Lee S; Bae S; Han S; Jang JY; Park T
Biomed Eng Online; 2014; 13 Suppl 2(Suppl 2):S5. PubMed ID: 25560450
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma.
Yan TT; Fu XL; Li J; Bian YN; Liu DJ; Hua R; Ren LL; Li CT; Sun YW; Chen HY; Fang JY; Hong J
Oncotarget; 2015 Nov; 6(35):37028-42. PubMed ID: 26498693
[TBL] [Abstract][Full Text] [Related]
38. The next "sweet" spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection.
Xu Y; Wang Y; Höti N; Clark DJ; Chen SY; Zhang H
Mass Spectrom Rev; 2023 Mar; 42(2):822-843. PubMed ID: 34766650
[TBL] [Abstract][Full Text] [Related]
39. IL-8-Positive Tumor-Infiltrating Inflammatory Cells Are a Novel Prognostic Marker in Pancreatic Ductal Adenocarcinoma Patients.
Fang Y; Saiyin H; Zhao X; Wu Y; Han X; Lou W
Pancreas; 2016; 45(5):671-8. PubMed ID: 26495785
[TBL] [Abstract][Full Text] [Related]
40. CEACAM7 expression contributes to early events of pancreatic cancer.
Dhasmana A; Dhasmana S; Kotnala S; Laskar P; Khan S; Haque S; Jaggi M; Yallapu MM; Chauhan SC
J Adv Res; 2024 Jan; 55():61-72. PubMed ID: 36828119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
